A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
Akeso and Summit Therapeutics reported Phase 3 Harmoni-6 results in China for ivonescimab (PD-1/VEGF) plus chemotherapy in squamous non-small-cell lung cancer. The drug cut the risk of death by 34% and improved median overall survival to 27.9 months vs 23.7 months with tislelizumab plus chemotherapy, according to an abstract ahead of ASCO. Summit shares have moved on global efficacy questions; Harmoni-3 global data are pending.
How this was made
The 30-second read
Why it matters
The article provides new Phase 3 overall survival results (Harmoni-6) in squamous non-small-cell lung cancer, including a 34% reduction in death risk and a median survival extension of ~4 months with chemo. It also flags key uncertainties: the trial was conducted exclusively in China, the control group lived longer than expected, and bleeding rates were higher in the ivonescimab arm.
Market read
A statistically significant overall survival win in a closely watched late-stage China trial is a meaningful catalyst for the ivonescimab program and for Summit’s ex-China development expectations, but global translation risk remains central.
What to watch
Bleeding occurred in ~25% (higher than control), and the clinical meaningfulness of a ~4-month median OS gain may vary by patient and endpoint hierarchy.
Background
Ivonescimab is a PD-1/VEGF bispecific antibody; it targets pathways analogous to Keytruda (PD-1) and Avastin (VEGF) and has been debated as a potential successor to Keytruda.
Ticker impact
Summit Therapeutics licensed ivonescimab rights outside China and its stock reaction is tied to the new Phase 3 overall survival data and global-readthrough concerns.
Near-term volatility likely: initial upside from OS benefit, offset by skepticism about representativeness and bleeding safety.
The article links the news directly to Summit’s prior surge and recent pullback, and provides new OS datapoints plus safety/interpretation concerns.
Market effects
Re-energizes the PD-1/VEGF bispecific debate versus Keytruda/Opdivo, potentially shifting expectations for next-gen checkpoint combinations and safety tradeoffs.
China-only Phase 3 design raises questions about regional efficacy differences, which can affect how investors price global development risk.
Global Phase 3 Harmoni-3 is ongoing; results will likely become the key determinant for whether ivonescimab can translate beyond China.
Counterpoint
The OS advantage may be overstated due to control-arm outperformance and non-representative enrollment; investors may discount the China-only signal until global Harmoni-3 confirms.
Key entities
- drugivonescimab
Experimental PD-1/VEGF bispecific antibody showing statistically significant overall survival improvement in a China Phase 3 trial.
- companySummit Therapeutics
Licensed ivonescimab rights outside China; its stock is highlighted as reacting to the trial results and global-readthrough concerns.
- companyAkeso
Source company of ivonescimab; trial results support the clinical value of its oncology pipeline.
